Preclinical studies in rodent and non-human primate models of GBA1-associated PD demonstrated that cisterna magna injection of PR001 leads to widespread vector biodistribution, robust transgene expression in cortical and subcortical regions, increased GCase activity and reductions in α-synuclein accumulation. This evidence concerns the gene GBA1 and Parkinson disease.